A phase II study of nab-Paclitaxel therapy in reductive dose for patients with advanced/recurrent gastric cancer after prior treatments including fluoropyrimidine (OGSG 1302)
Latest Information Update: 28 Feb 2020
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium
- 22 Jan 2020 Status changed from active, no longer recruiting to completed.
- 07 Oct 2018 Planned End Date changed from 31 Dec 2019 to 19 Dec 2018.